penn medicine
penn surgery
penn surgery home penn surgery clinical penn surgery education penn surgery research penn surgery administration

Douglas L. Fraker, M.D.
Endocrine and Oncologic Surgery

 
  • Profile Home
  • Appointments
  • Education
  • Societies
  • Research
  • Publications
  • Awards

Administrative Office:
Hospital of the University of Pennsylvania
3400 Spruce Street
4 Silverstein Pavilion
Philadelphia, PA 19104
Executive Assistant: Carla Tolino-Panaccio
Administrative Telephone: 215-662-7866
Administrative Fax: 215-662-3629
Patient Appointments: 215-615-5858

Clinical Office:
Perelman Center for Advanced Medicine
Abramson Cancer Center
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104

Contact Information (internal use only)

frakerd@uphs.upenn.edu

 

Dr. Douglas Fraker is Chief of the Division of Endocrine and Oncologic Surgery as well as a surgical oncologist and an endocrine surgeon, who was formally a senior investigator at the National Cancer Institute. Dr. Fraker’s research efforts have focused on regional perfusion to treat melanoma and soft tissue sarcomas of the extremities and metatastic tumors of the liver. His clinical practice deals primarily with surgical oncology (including melanoma, sarcoma, and liver tumors) and endocrine surgery of the thyroid, parathyroid, adrenal and pancreas. Clinical research protocols include isolated limb perfusion for melanoma and sarcoma, intra arterial chemotherapy for liver tumors, and photodynamic therapy for intra peritoneal disease. Research interests include mechanism of action of tumor necrosis factor, treatment strategy targeting tumor angiogenesis, regional gene therapy, and photodynamic therapy.

Special Interests:
Treatment of primary and metastatic liver tumors by resection, radiofrequency thermal ablation, intra-arterial pump for chemotherapy; and sentinel lymph node mapping; treatment of melanoma with sentinel lymph node mapping and biopsy, and isolated limb perfusion; gastrointestinal cancers of the esophagus, stomach, colon and rectum; thyroid cancer; parathyroid disease; pancreatic islet cell tumors; carcinoid; adrenal tumors including laparoscopic adrenalectomy; gastrointestinal sarcomas; use of photodynarnic therapy for treatment of intraperitoneal malignancies (carcinomatosis and sarcomatosis, including ovarian cancer).

 
Faculty Appointments
2011 - present Jonathan E. Rhoads Professor of Surgical Science
Perelman School of Medicine
Philadelphia, Pennsylvania
 
1995 - 2011 Jonathan E. Rhoads Associate Professor of Surgical Science
Perelman School of Medicine
Philadelphia, Pennsylvania
 
1993 - 1995 Assistant Professor of Surgery
Uniformed Services University of the Health Sciences
Bethesda, Maryland
 
Hospital and Administrative Appointments
2009 - present Vice Chairman for Research
Department of Surgery, University of Pennsylvania
Philadelphia, Pennsylvania
 
2007 - 2013 Deputy Director
Clinical Services and Programs
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania
 
2002 - 2009 Vice Chairman for Clinical Affairs
Department of Surgery, University of Pennsylvania
Philadelphia, Pennsylvania
 
2002 - 2008 Director of General Surgery
Department of Surgery, University of Pennsylvania
Philadelphia, Pennsylvania
 
2002 - 2009 Director, Outpatient Clinic
Department of Surgery, University of Pennsylvania
 
1995 - present

Chief, Division of Surgical Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

 
1995 - present Director, Laboratory of Surgical Oncology
University of Pennsylvania Cancer Center
 
1992 - 1995 Head, Surgical Metabolism Section
Surgery Branch, National Cancer Institute, NIH
Bethesda, Maryland
 
1992 - 1995 Director, Endocrine Surgery Service
National Institutes of Health
Bethesda, Maryland
 
1991 - 1995 Senior Investigator, Surgical Metabolism Section
Surgery Branch, National Cancer Institute, NIH
Bethesda, Maryland
 
1991 - 1995 Attending Surgeon
NIH, Clinical Center, Surgery Branch
Bethesda, Maryland
 
Education/Training
1983 MD - Harvard Medical School (Magna Cum Laude)
 
1979 BA - University of Wisconsin (Highest honors)
 
Postgraduate Training and Fellowship Appointments
1990 - 1991 Chief Resident in Surgery, University of California
San Francisco, California
 
1989 - 1990 Senior Resident in Surgery, University of California
San Francisco, California
 
1986 - 1989 Medical Staff Fellow, Surgery Branch, National Cancer Institute
Bethesda, Maryland
 
1984 - 1986 Junior Resident in Surgery, University of California
San Francisco, California
 
1983 - 1984 Intern in Surgery, University of California
San Francisco, California
 
Memberships/Societies
 
National Societies/Organizations
2013 - present Member,  AACR Pancreatic Cancer Research Grants Scientific Review Committee
 
2011 Member, Executive Committee American Association of Endocrine Surgeons
 
2010 Chairperson, Clinical Endocrinology Subcommittee, Endocrinology Section
2010 AACR Program Committee
 
2008 Member, Grants Review Committee, “Innovative Research Programs to Improve
Health and Healthcare” Research Competitiveness Program at the American
Association for the Advancement of Science
 
2007 Member, Society of Surgical Oncology American Board of Surgery Task Force
 
2007 - 2010 Member,  Surgical Forum Committee, American College of Surgeons
 
2006 - 2007 Member, NIH NCI-F Review Committee
 
2005 - 2006 Member,  General Motors Cancer Research Award Committee
 
2004 Member, Grants Selection ASCO Advanced Clinical Research Award  in Breast Cancer
 
2003 Associate Examiner, American Board of Surgery, oral examinations
 
2003 - 2004 Director, James Ewing Foundation of the Society of Surgical Oncology
 
2003 - 2005 Member, Nominating Committee, Society of Surgical Oncology
 
2001 - 2004 Member, Grants Selection Committee, American Society of Clinical Oncology
 
2001 - 2004 Councilman at Large, Executive Committee, Society of Surgical Oncology
 
2000 - 2003 Member, Issues and Government Affairs Committee, Society of Surgical Oncology
 
1999 - 2003 Examination Consultant, American Board of Surgery Qualifying Examination Committee
 
1999 - 2003 Member, Melanoma Intergroup Committee
 
1998 Associate Examiner, American Board of Surgery, oral examinations
 
1998 - present

American College of Surgeons Oncology Group
Deputy Chair, 1997 - 1998
Member, Executive Committee, 1997 - 2004
Chair, Melanoma Committee, 1998 - 2003
Member, Hepatobiliary Committee 1998 - present
Member, Endocrine Committee 1998 - 2005
Member, Sarcoma Committee, 1998 - 2005
Member Melanoma Committee, 1998 - 2005
Chair, Constitution & Bylaws Committee, 2002 - 2003

 
1996 - 2001 Melanoma and Sarcoma Subcommittee, American Society of Clinical Oncology
 
Research

There are two main areas of basic research occurring in the laboratory of Dr. Douglas Fraker. Both areas relate to his interest in regional treatment of advanced cancers.

  1. The first area of research involves the use of melphalan with acidic perfusate. We have developed an animal model in which isolated limb perfusion (ILP) is performed on nude rats that have been xenografted with human melanoma, sarcoma, and colon carcinoma. In each of these tumors, a change in the pH of the perfusate from 7.4 to between 6.8 and 6.9 markedly enhances the tumor response to melphalan, and in fact, the majority of tumors undergo a complete regression. In addition, in limbs with xenografted melanoma, levels of nitric oxide have been found to be increased after perfusion with acidic media, and this effect is seen only in limbs that have xenografted tumor (tumor specific). It is believed that this burst of nitric oxide may play an important role in the enhanced tumor response that is seen. Specifically, since nitric oxide is a powerful modulator of vessels, it is believed that the tumor vasculature may be negatively affected by the acute increase in nitric oxide levels. Another mechanism that has been postulated to explain the effect of acidic perfusate includes the induction of apoptosis of tumor cells by the higher levels of nitric oxide. These potential mechanisms are currently being investigated both in vitro and in vivo in our animal model. Ultimately, it is hoped that the mechanisms for the enhanced tumor response with acidic perfusate may be delineated and eventually used in clinical trials and treatment.
  1. The second area of study is related to our ongoing clinical project of intraperitoneal photodynamic therapy for carcinomatosis and sarcomatosis of the abdomen. We currently have studies that involve the analysis of tissue specimens taken during clinical surgery and the development of an animal model to investigate the use of new photosensitizers.
 
Publications
 
Original Papers
  1. Auerbach, RA, Fraker DL and Sidky YA. Regional differences in tumor growth in mice. Fortschr. Zoology 26:133, 1981.
  2. Kerdel F, Fraker DL, and Haynes HA. Necrotizing vasculitis from radiographic contrast media. J Am Acad Derm 19:25, 1984.
  3. Fraker DL and Norton JA Reversal of the toxic effects of cachectin by insulin. Surg. Forum 38: 18-20, 1987.
  4. Fraker DL and Norton JA. Localization and resection of insulinomas and gastrinomas. JAMA 259:3601-3605, 1988.
  5. Fraker DL, Stovroff MC, Merino MJ, and Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med 168:95-105, 1988.
  6. Stovroff MC, Fraker DL, Swedenborg JA and Norton JA. Cachectin/tumor necrosis factor: A possible medator of cancer anorexia in the rat. Cancer Res 48:4567-4572, 1988.
  7. Fraker DL, Norton JA, Saeed ZE, Maton PN, Gardner JD, Jensen RT. A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery 104:1054-1063, 1988.
  8. Fraker DL and Norton JA TNF and endotoxin: cross-tolerance by different mechanisms. Surg. Forum 39: 15-18, 1988.
  9. Evans S, Matthews W, Perry R, Fraker DL, Norton JA and Pass HI. Photodynamic therapy stimulates murine peritoneal macrophages to produce tumor necrosis factor. Surg. Forum 40: 421-423, 1989.
  10. Langstein HN, Fraker DL and Norton JA. Reversal of cancer cachexia by antibodies to interferon-gamma but not cachectin/tumor necrosis factor. Surg. Forum 40: 408-410, 1989.
  11. Stavroff MC, Fraker DL, Norton JA. Cachectin activity in the serum of cachectin, tumor-bearing rats. Arch Surg 124:94-99, 1989.
  12. Norton JA and Fraker DL. Tolerance to tumor necrosis factor. Nutrition 5:131-135, 1989.
  13. Stovroff NC, Fraker DL, Travis WD and Norton JA. Altered macrophage activity and tumor necrosis factor: tumor necrosis and host cachexia. J Surg Res 46:462-469, 1989.
  14. Fraker DL, Merino MJ and Norton JA. Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol 256:E725-E731, 1989.
  15. Sheppard BC, Fraker DL, and Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 106:156-162, 1989.
  16. Fraker DL, Langstein HN and Norton JA. Passive immunization against tumor necrosis factor partially abrogates interleukin-2 toxicity. J Exp Med 170:1015-1020, 1989.
  17. Evans S, Matthews W, Perry R, Fraker DL, Norton JA and Pass HI. Photodynamic therapy of macrophages: energy dependent production of tumor necrosis factor. J Natl Cancer Inst 82:34-39, 1990.
  18. Jensen JC, Buresh CM, Fraker DL, Langstein HL, Doherty GM, Alexander HR and Norton JA. Enhanced cytokine gene expression in cachectic tumor bearing rats. Surg. Forum 41, 1990.
  19. Fraker DL, Doppman JL, Shawker TH, Marx SJ, Spiegal AM, and Norton JA. Undescended parathyroid adenoma: an important etiology for failed operations for primary hyperparathyroidism. World J Surg 14:342-348, 1990.
  20. Fraker DL, Sheppard BC and Norton JA. Impact of tolerance on anti-tumor efficacy of tumor necrosis factor in mice. Cancer Res 50:2261-2267, 1990.
  21. Darling G, Fraker DL, Jensen JC, Gorschboth CM and Norton JA. Cachectic effects of recombinant tumor necrosis factor in rats. Cancer Res 50:4008-4013, 1990.
  22. Sheppard BC, Venzon D, Fraker DL, Langstein HN, Jensen JC, and Norton JA. Prolonged survival of tumor bearing rats with repetitive low dose recombinant tumor necrosis factor. Cancer Res 50:3928-3933, 1990.
  23. Norton JA, Shawker TH, Doppman JL, Miller DL, Fraker DL, Cromack DT, Gordon P and Jensen RT. Localization and surgical treatment of occult insulinomas. Ann Surg 212:615-620, 1990.
  24. Danforth DR and Fraker DL. Splenectomy for the massively enlarged spleen. American Surg 57:108-113, 1991.
  25. Fraker DL, Travis WD, Merendino JJ, Zimering MB, Streetan EA, Weinstein LS, Marx SJ, Spiegal AM, Aurbach GD, Doppman JL and Norton JA. Locally recurrent parathyroid neoplasms as a cause for recurrent and persistent primary hyperparathyroidism. Ann Surg 213:58-65, 1991.
  26. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, Walker EC, Fraker DL, Stovroff MC and Norton JA. Treatment with recombinant tumor necrosis factor alpha protects rats against the lethality, hypotension, and hypothermia of gram negative sepsis. J Clin Invest 88:34-39, 1991.
  27. Langstein HN, Doherty GM, Fraker DL, Buresh CM and Norton JA. The roles of interferon-gamma and tumor necrosis factor in an experimental rat model of cancer cachexia. Cancer Res 51:2302-2306, 1991.
  28. Alexander HR, Doherty GM, Fraker DL, Block MI, Swedenborg JA and Norton JA. Human recombinant interleukin-1 protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res 50:421-424, 1991.
  29. Norton JA, Shawker TH, Doppman JL, Miller DL, Fraker DL, Cromack DT, Gorden P, Jensen RT. Letter to Editor. Ann Surg 215:87-88, 1992.
  30. Fraker DL, Thom AK, Doherty GM, Langstein HN, Buresh CM, Norton JA. Tumor necrosis factor mediates the survival benefit of interleukin-2 in a murine pulmonary metastases model. Surg Oncology 1:1-9-, 1992.
  31. Alexander HR, Wong GH, Doherty GM, Venzon D, Fraker DL, Norton JA. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with IL-1 and TNF. J Exp Med 175:1139-1142, 1992.
  32. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, Norton JA. Recombinant interleukin-1 receptor antagonist (IL-1ra): Effective therapy against gram-negative sepsis in rats. Surgery 112:194-199, 1992.
  33. Thom AK, Fraker DL, Taubenberger JK, Norton JA. Effective regional therapy of experimental cancer with paralesional administration of tumor necrosis factor ? + interferon-?. Surg Oncology 1:291-298, 1992.
  34. Alexander HR, Grem J, Pass HI, Hamilton M, McAtee N, Fraker DL, Allegra C. Neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. Oncology 7:37-42, 1993.
  35. Block MI, Berg M, McNamara MJ, Norton JA, Fraker DL, Alexander HR. Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J Exp Med 178:1085-1090, 1993.
  36. Thom AK, Fraker DL, Norton JA. IL-1 receptor antagonist (IL-1ra) augments IL-2 induced pulmonary vascular leak. J Surg Res 54:336-341, 1993.
  37. Sugg SL, Norton JA, Fraker DL, Metz DC, Pisegna JR, Fishbeyn V, Benya RV, Shawker TH, Doppman JL, Jensen RT. A prospective study of intraoperative methods to find and resect duodenal gastrinomas. Ann Surg 218:138-144, 1993.
  38. Metz DC, Kuchio M, Fraker DL, Venzon DJ, Jaffe G, Jensen RT, Stoffer-Stevenson M. Flow cytometry and Zollinger-Ellison Syndrome: relationship to clinical course. Gastroenterology 105:799-813, 1993.
  39. Zeiger MA, Fraker DL, Pass HI, Nieman LK, Cutler BG, Jr., Chrousos GP, Norton JA. Effective reversibility of the signs and symptoms of hypercortisolism by bilateral adrenalectomy. Surgery 114:1138-1143, 1993.
  40. Sugg SL, Fraker DL, Alexander HR, Doppman JL, Miller DL, Chang R, Skarulis MC, Marx SJ, Spiegel AM, Norton JA. Prospective evaluation of selective venous sampling for parathyroid hormone concentration in patients undergoing reoperations for primary hyperparathyroidism. Surgery 114:1004-1010, 1993.
  41. Pisegna JR, Slimak GG, Strader DB, Metz DC, Orbuch M, Fishbeyn VA, Fraker DL, Norton JA, Maton PN, Jensen RT. Use of human recombinant alpha interferon in patients with metastatic gastrinoma: A prospective study. Gastroenterology 105:1179-1183, 1993.
  42. Block MI, Arnold WS, Fraker DL, Alexander HR. D-Factor mediates IL-6 but not IL-1 production following TNF administration in vivo. Surg Forum, 44: 95-96, 1993.
  43. Fraker DL, Alexander HR. The use of TNF in isolated limb perfusion: Results and side effects. The NCI results. Melanoma Research, 4:(51) 27-29, 1994.
  44. Brundage SI, Block MI, Billingsley KG, Fraker DL, Alexander HR. Role of leukemia inhibitory factor (LIF) in experimental sepsis. Surg Forum, 45: 1-3, 1994.
  45. Arnold WS, Tannenbaum SH, Yu KC, Alexander HR, Fraker DL. Effects of human fibrosarcoma tumor supernatant on endothelial cells(EC):Induction of tissue factor (TF) expression and augmented expression of adhesion molecules in response to tumor necrosis factor (TNF) Surg Forum, 45: 548-550, 1994.
  46. Billingsley KG, Strassmann G, Arnold WS, Fraker DL, Alexander HR. Monocytes augment production of interleukin-6 (IL-6) and leukemia inhibitory factor (LIF) by human tumor cell lines. Surg Forum, 45: 471-474, 1994.
  47. Doppman JL, Nieman LK, Cutler GB, Jr, Chrousos GP, Fraker DL, Norton JA, Jensen RT. Adrenocroticotropic hormone-secreting islet cell tumors: Are they always malignant? Radiology 190:59-64, 1994.
  48. Charnas L, Luciano C, Gilliat R, Dalakas M, Ishak K, Fraker DL, Gahl WA. Distal myopathy in nephropathic cystinosis. Ann Neurol 35:181-188, 1994.
  49. Wertheimer BM and Fraker DL. Cause of hypotension after isolated limb perfusion with tumor necrosis factor. Anesthesiology 80:961, 1994.
  50. Avila NA, Shawker TH, Fraker DL. Color flow doppler ultrasound in metastatic melanoma to the gallbladder. J Clin Ultrasound 22:342-347, 1994.
  51. Jensen RT and Fraker DL. Zollinger-Ellison syndrome: Advances in the management of the gastric hypersecretion and the gastrinoma. JAMA 271:1429-1435, 1994.
  52. Berg M, Fraker DL, Alexander HR. Characterization of recombinant D-factor/leukemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-LI adipocytes. Cytokine 6:425-432, 1994.
  53. Fraker DL, Norton JA, Alexander HR, Venzon DC, Jensen RT. Surgery in Zollinger Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220:320-330, 1994.
  54. Alexander HR, Billingsley KG, Block MI, Fraker DL. D-Factor/Leukemia inhibitory factor: Evidence for its role as a mediator of acute and chronic inflammatory disease. Cytokine 6:589-596, 1994.
  55. Billingsley KG, Fraker DL, Doppman JL, Norton JA, Shawker TH, Skarulis M, Marx SJ, Spiegel AM, Alexander HR. Localization and operative management of undescended parathyroid adenomas in patients with persistent primary hyperparathyroidism. Surgery 116:982-990, 1994.
  56. MacFarlane MP, Fraker DL, Shawker TH, Norton JA, Doppman JL, Chang RA, Skarulis M, Marx SJ, Spiegel AM, Alexander HR. Use of preoperative fine needle aspiration in patients undergoing reoperations for primary hyperparathyroidism. Surgery 116:959-965, 1994.
  57. Arnold WS, Fraker DL, Alexander HR, Weber HC, Norton JA, Jensen RT. Apparent lymph node primary gastrinoma. Surgery 116:1123-1130, 1994.
  58. Fraker DL, Alexander HR, Thom AK. Use of tumor necrosis factor in isolated hepatic infusion. Circulatory Shock 44:45-50, 1994.
  59. Doppman JL, Shawker TH, Fraker DL, Alexander RB, Skarulis MC, Spiegel AM. Parathyroid adenoma within the vagus nerve. Am J Roent 163:943-945, 1994.
  60. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-? and melphalan. J Clin Oncol 13:264-273, 1995.
  61. Alexander HR, Grem JL, Hamilton JM, Pass HI, Hong M, Fraker DL, Steinberg SM, McAtee N, Allegra CJ, Johnston PG. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal edenocarcinoma, Cancer J Sci Amer 1:49-54, 1995.
  62. Weber HC, Venzon DJ, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA, Jensen RT. Determinants of metastatic rate and survival in Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 108:1637-1649, 1995.
  63. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Palliation of regional syptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high dose tumor necrosis factor. Cancer J Sci Amer 1:122-130, 1995.
  64. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, Collier ES, Skarulis MC, Gorden P. Localization of insulinomas by intra-arterial stimulation with calcium. Ann Intern Med 123:269-273, 1995.
  65. Gorden P, Skarulis MC, Roach P, Comi RJ, Fraker DL, Norton JA, Alexander HR, Doppman JL. Plasma proinsulin-like component in insulinoma: A 25 year experience. J Clin Endocrinol Metabol 80:2884-2887, 1995.
  66. Yu KC, Alexander HR, Ziessman HA, Norton JA, Doppman JL, Buell JF, Nieman LK, Cutler GB, Jr, Chrousos GP, Fraker DL. Role of pre-operative iodocholesterol scintiscanning in patients undergoing adrenalectomy for Cushing's syndrome. Surgery 118:981-987, 1995.
  67. MacFarlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 118:1108-1113, 1995.
  68. Amikura K, Alexander HR, Norton JA, Doppman JL, Jensen RT, Nieman L, Cutler G, Chrousos G, Fraker DL. The role of surgery in management of ACTH-producing islet cell tumors of the pancresa. Surgery 118:1125-1130, 1995.
  69. Block MI, Fraker DL, Strassmann G, Billingsley KG, Arnold WS, Perlis C, Alexander HR. Endogenous D-factor activity partiallly mediates the toxic but not the therapeutic effects of tumor necrosis factor. Int J Cancer 63:245-249, 1995.
  70. Fraker DL. Commentary on "Percutaneous Radiofrequency Interstitial Thermal Ablation in the Treatment of Small Hepatocellular Carcinoma: Report of 24 Patients". The Cancer Journal, 1: 30-31, 1995.
  71. Yang JC, Fraker DL, Thom AK, Pass HI, Rosenberg SA. Isolation perfusion with tumor necrosis factor-?, interferon-? andhyperthermia in the treatment of localized and metastatic cancer. Recent Results Cancer Res. 138: 131-136, 1995.
  72. Fraker DL, Alexander HR. Use of high-dose tumor necrosis factor in isolation perfusion of the limbs and liver. Reg Canc Treat, 1996.
  73. Alexander HR, Fraker DL. Continuous hyperthermic peritoneal perfusion with cisplatin in the treatment of peritoneal carcinomatosis. Canc Treat & Research, 81:41-50, 1996.
  74. Fraker DL, Norton JA. Pancreatic islet cell tumor - Insulinoma: Discussion of a case presentation. Postgraduate General Surgery, 1996.
  75. Ma G, Turner E, Jaskowiak N, Sarraf P, Bartlett D, Fraker DL, Alexander HR. Obese gene expression is acutely regulated by tumor necrosis factor during sublethal endotoxemia in mice. Surg Forum XLVII:17-20, 1996.
  76. Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 22:1242-1247, 1996.
  77. Chen CC, Skarulis MC, Fraker DL, Alexander HR, Marx SJ, Spiegel AM. Technetium-99m Sestamibi imaging before reoperation for primary hyperparathyroidism. J Nucl Med 36:2186-2191, 1995.
  78. Buell JF, Fraker DL, Doppman JL, Shawker TH, Skarulis MC, Spiegel AM, Marx SJ, Alexander HR. High cervical intravagal hypercellular parthyroid gland as the etiology of severe persistent primary hyperparathyroidism. American Surgeon 61:943-946, 1995.
  79. Yu KC, Fraker DL, Ziessman HA. Atlas of iodocholesterol scintigraphy (NP-59) in Cushing's syndrome with CT and MR correlation. Clin Nucl Med, 21:136-41, 1996.
  80. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: Results of a TNF dose escalation study. J Clin Oncol 14:479-489, 1996.
  81. Brucker-Davis F, Reynolds JC, Skarulis MC, Fraker DL, Alexander HR, Weintraub BD, Robbins J. Two unusual causes of "false-positive" iodine-131 whole body scans for differentiated thyroid cancer. J Nucl Med, 37:1690-3, 1996.
  82. Billingsley KG, Fraker DL, Strassmann G, Loeser C, Alexander HR. Macrophage derived tumor necrosis factor augments tumor production of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia. Ann Surg Oncol 3(1):29-35, 1996.
  83. Buell JF, Alexander HR, Norton JA, Yu KC, Fraker DL. Bilateral adrenalectomy for Cushing's syndrome: Anterior versus posterior surgical approach. Ann Surg, 225(1):63-68, 1997.
  84. Doppman JL, Skarulis MC, Chen CC, Chang R, Pass HI, Fraker DL, Alexander HR, Niederle B, Marx S,Norton JA, Wells SA, Spiegel AM. Parathyroid adenoma in the aortopulmonary window. Am J Radiol 201:456-462, 1996.
  85. Jaskowiak NT, Fraker DL, Alexander HR, Norton JA, Doppman JL, Jensen RT. Is reoperationfor gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery 120(6):1055-62, 1996.
  86. Jaskowiak N, Norton JA, Alexander HR, Doppman JL, Shawker T, Skarulis M, Marx S, Spiegel A, Fraker DL. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 224(3):308-322, 1996.
  87. Merryman P, Tannenbaum SH, Gralnick HR, Yu K, Arnold WS, Alexander HR, Fraker DL, Horne MK. Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-?, and/or melphalan. Thrombosis and Haemostasis, 77(1):53-56, 1997.
  88. Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ, Flier JS, Lowell BB, Fraker DL, Alexander HR. Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia. J Exper Med, 185(1):171-175, 1997.
  89. Buell JF, Reed E, Lee KB, Parker RJ, Venzon DJ, Amikura K, Arnold WS, Fraker DL, Alexander HR. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Ann Surg Onc, 4(2):141-148, 1997.
  90. Orel SG, Reynolds C, Schnall MD, Solin LJ, Fraker DL, Sullivan DC. Breast carcinoma: MR Imaging before re-excisional biopsy. Radiology 205:429-436, 1997.
  91. Wu PC, Alexander HR, Bartlett DL, Doppman JL, Fraker DL, Norton JA, Gibril F, Fogt F, Jensen RT. A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery, 122(6):1176-1182, 1997.
  92. Libutti SK, Bartlett DL, Jaskowiak NT, Skarulis M, Marx SJ, Spiegel AM, Fraker DL, Doppman JL, Shawker TJ, Alexander HR. The role of thyroid resection during reoperation for persistent or recurrent hyperparathyroidism. Surgery, 122(6):1183-1188, 1997.
  93. van de Rijn M, Barr FG, Xiang QB, Salhany KE, Fraker DL, Fisher C. Radiation associated synovial sarcoma. Human Pathology, 28:1325-1328, 1997.
  94. Brown CK, Bartlett DL, Doppman JL, Gorden P, Libutti SK, Fraker DL, Shawker TH, Skarulis MC, Alexander HR. Intra-arterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery 122(6):1189-93, 1997.
  95. Vargas HI, Kavoussi LR, Bartlett DL, Wagner JR, Venzon DJ, Fraker DL, Alexander HR, Lindhan WM, Walther MM. Laparoscopic adrenalectomy: a new standard of care. Urology 49(5):673-8, 1997.
  96. Fraker DL. Isolated limb perfusion: A Case Study. Melanoma Newsletter, 1997.
  97. Pingpank JF, Fraker DL. An in vivo model demonstrating that tumor necrosis factor targets tumor endothelium. Surg Forum XLVIII:804-806, 1997.
  98. Hahn SM, Sindelar WF, Delaney TF, Rubin SC, Fraker DL, Hsi RA, Glatstein E. Intraperitoneal PDT for the treatment of recurrent ovarian cancer. Photomedicine in Gynecology and Reproduction 7:21, 1998.
  99. Park BJ, Huang J, Royalty D, Libutti SK, Skarulis MC, Jensen RT, Fraker DL, Gorden P, Norton JA, Alexander HR, Bartlett DL. Operative management of islet-cell tumors (ICTS) arising in the head of the pancreas. Surgery, 124:1056-1062, 1998.
  100. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer, 80, 2084-90, 1997.
  101. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. Journal of Clinical Oncology, 16(4):1479-1489, 1998.
  102. Alexander HR, Fraker DL, Norton JA, Bartlett DL, TioL, Benjamin SB, Doppman JL, Goebel SU, Serrano J, Gibril F, Jensen RT. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Annals of Surgery, 228(2):228-238, 1998.
  103. Kammen BF, Elder D, Fraker DL, Siegelman ES. Extraadrenal myelolipoma: MR imaging findings. American Journal of Roengenology, 171(3):721-723, 1998.
  104. Alexander HR, Bartlett DL, Venzon DT, Libutti SK, Doppman JL, Fraker DL, Norton JA, Gibril F, Jensen RT. Analysis of factors associated with long-term cure in patients undergoing operation and resection for Zollinger-Ellison syndrome (ZES). Surgery, 124:1160-6, 1998.
  105. Lempreave JL, Benard F, Alavi A, Jimenez-Hoyuela J, Fraker DL. Positron emission tomography evaluation of therapeutic limb perfusion in Merkel’s cell carcinoma. J Nucl Med, 39:2067-2090, 1998.
  106. Li S, Fraker DL, van de Rijn M. Desmoplastic fibroblastoma (collagenous fibroma): a case report and a review of literature. Human Pathology, In Press,1998.
  107. Sanchez-Ortiz RF, Fraker DL, Malkowicz SB. Renal cell carcinoma presenting with mesenteric thrombosis and anticardiolipin antibodies: Echoes of Trousseau’s Syndrome? Journal of Urology, 159:2078, 1998.
  108. Abraham SC, Fox K, Fraker DL, Solin L, Reynolds C. Sampling of grossly benign breast re-excisions: A multidisciplinary approach to assessing adequacy. American Journal of Surgical Pathology, 23(3):316-322, 1999.
  109. Norton J, Doherty GM, Fraker DL, Alexander HR, Doppman J, Venzon DJ, Gibril F, Jensen RT. Surgical treatment of localized gastrinoma within the liver: A prospective study. Surgery, 124:1145-1152, 1998.
  110. Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant E, Orel S, Berlin J, Helsabeck C, Fraker DL, Reynolds C. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel node biopsy in patients with breast cancer. Cancer, 85:1098-1103, 1999.
  111. Bedrosian I, Scheff AM, Mick R, Callans LS, Bucky LP, Spitz FR, Helsabeck C, Elder DE, Alavi A, Fraker DL, Czerniecki BJ. Technetium-99m human serum albumin: An effective radiotracer for identifying sentinel lymph nodes in melanoma. Journal of Nuclear Medicine, 40:1143-1148, 1999.
  112. Orel SG, Weinsteinn SP, Schnall MD, Reynolds CA, Schuchter L, Fraker DL, Solin LJ. Breast MR Imaging of patients with axillary node metastases and unknown primary malignancy. Radiology, 212:543-49, 1999.
  113. Desai SS, Loh E, Kochman ML, Fraker DL, DeNofrio D. DeNovo ampullary neuroendocrine tumor in an orthotopic heart transplant recipient.. Am J Gastroenterol 94:3382-83, 1999.
  114. Engbrecht B, Menon C, Kachur A, Hahn S, Fraker DL. Photofrin-mediated phodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Research, 59:4334-42,1999.
  115. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT. Surgery to cure the Zollinger-Ellison Syndrome. NEJM 341(9):635-90, 1999.
  116. Feldman AL, Alexander HR, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 6(6):562-67, 1999.
  117. Feldman AL, Sharaf RN, Skarulis MC, Bartlett DL, Libutti SK, Weinstein LS, Marx SJ, Norton JA, Fraker DL, Alexander HRl. Results of heterotropic parathyroid autotransplantation: a 13 year experience. Surgery 126:102-48, 1999.
  118. Iyer M, Prabakaran I, Menon C, Fraker DL. Tumor necrosis factor downregulates vascular endothelial growth factor receptor Flk-1 in vivo. Surg Forum L:311-313, 1999.
  119. Mulvany KP, Prabakaran I, Xu S, Khorrami C, Menon C, Czerniecki B, Fraker DL, Callans LS. Human monocyte-derived dendritic cells transduced with recombinant adenovirus present melanoma antigen gp100 to cytotoxic T lymphocytes in vitro. Surg Forum L:309-310, 1999.
  120. Polin GM, Bauer TW, Buerk D, Hsi A, Prabakaran I, Menon C, Fraker DL. Eppendorf po2 histography and recessed po2 microelectrode as methods of measuring oxygen tension in a murine tumor model. Surg Forum LI 51:296-8, 2000.
  121. Hahn SM, Fraker DL, Zhu T, Yodh A, Rodriguez C, Smith D, Currens A, Glatstein E. Intraperitoneal photodynamic therapy for peritoneal carcinomatosis and sarcomatosis. Proceedings of SPIE 3909:2-9, 2000.
  122. Bedrosian I, Scheff AM, Callans LS, Spitz FR, Helsabeck C, Guerry D, Wolfe J, Elenitsas R, Elder DE, Bucky LP, Fraker DL, Czerniecki BJ. Incidence of sentinel node metastasis in patients with primary melanoma (<or=1mm) with vertical growth phase. Ann Surg Oncol 7(4):262-7, 2000.
  123. Vulcan TG, Zhu T, Rodriguez D, His A, Fraker DL, Baas P, Murrer L, Starr WM, Yodh AG, Hahn SM.Comparison between isotropic and monisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers in Surgery and Medicine 26(3):292-301, 2000.
  124. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, Farley DR, Heller R, Conant E, Lawton T, Fraker DL, Czerniecki BJ. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88(11):2540-5, 2000.
  125. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A Phase I-II Study of Isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6:3062-3070, 2000.
  126. Libutti SK, Bartlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. Journal of the American College of Surgeons, 191:519-530, 2000.
  127. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, Glatstein E, Fraker DL. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 8:65-71, 2001.
  128. Evans SA, Hahn S, Magarelli DP, Zhang P, Jenkins T, Fraker DL, Hsi A, McKenna WG Koch CJ. Hypoxia in human intraperitoneal and extremity sarcomas. Int J Rad Oncol Biol Phys, 49(2):587-596, 2001.
  129. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki B, Rosato EF, Tomaszewski JE, Conant EF, Orel SB, Schuchter L, Fox K, Zieber N, Glick JH, Solin LJ. The impact of a multidisciplinary breast cancer clinic on patient management decisions: The University of Pennsylvania experience. Cancer, 91:1231-1237, 2001.
  130. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129:176-87, 2001.
  131. Menon C, Kutney SN, Lehr SC, Hendren SK, Busch TM, Hahn SM, Fraker DL. Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy. Clinical Cancer Research 7:3904-3911,2001.
  132. Baloch ZW, Hendren S, Gupta PK, LiVolsi VA,, Mandel SJ, Weber R, Fraker D. Inter-institutional review of thyroid FNA: Impact on clinical management of thyroid nodules. Diagnostic Cytology 25:231-234, 2001.
  133. Tada H, Barsoum J, Masconi D, Tazelaar J, Xie Q, Davis A, Fraker DL, Wilson JM, Spitz FR. Systemic interferon-? gene therapy results in tumor regression, induction of apoptosis, and long-term survival in mice with established colorectal liver metastases. Journal of Clinical Investigation 108:83-95, 2001.
  134. Kivlen MH, Bartlett DL, Libutti SK, Skarulis MC, Marx SJ, Simonds WF, Weinstein LS, Jensen RT, McCart JA, Naik AM, Kranda KC, Brennan MF, Norton JA, Fraker DL, Alexander HR. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type I, Surgery 130:991-998, 2001.
  135. Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, Bedrosian I, Fraker DL, Bauer TL, Czerniecki BJ. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 2002, 9:169-176.
  136. Bauer TW, Hahn SM, Spitz FR, Kachur A, Glatstein E, Fraker DL. Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis. Ann Surg Oncol 8:254-259, 2001.
  137. Griffin GM, Zhu T, Solonenko M, Del Piero F, Kapakin A, Busch T, Yodh A, Polin G, Bauer T, Fraker DL, Hahn SM. Canine study of Motexafin Lutetium-mediated intraperitoneal photodynamic therapy. Clinical Cancer Research 7:374-381, 2001.
  138. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with MEN1 and Zollinger-Ellison Syndrome. Ann Surg 234:495-505, 2001.
  139. Kelley ST, Menon C, Fraker DL. Acidosis induces regression of human colon cancer metastases after isolated perfusion with and without melphalan. Surgical Forum 52:238-239, 2001.
  140. Baloch AW, Fraker D, LiVolsi VA. Parathyromatosis as Cause of Recurrent Secondary Hyperparathyroidism: A Cytological Diagnosis. Diagnostic Cytopathology, 25:403-405, 2001.
  141. Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL, Alexander HR. Factors affecting survival following complete response to isolated limb perfusion in patients with in transit melanoma. Ann Surg Oncol, 8:771-778, 2001.
  142. Prabakaran I, Menon C, Xu S, Gomez-Yafal, Czerniecki BJ, Fraker DL. Mature CD83 dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Annals of Surg. Oncology 9:411-418. 2002.
  143. Kelley ST, Menon C, Buerk DG, Bauer TW, Fraker DL. Acidosis plus melphalan induces nitric oxide mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery, 2002 ;132:252-258.
  144. Mercier GA, Alavi A, Fraker DL. FDG-PET and isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results. Clinical Nuclear Medicine, 26:832-836, 2001.
  145. Metz JM, Tochner Z, Hahn S, Smith D, Zhu T, Friedberg JS, Fraker DL, Glatstein E. Clinical applications for photodynamic therapy in oncology. Proceedings of SPIE 4248:1605-1622.
  146. Maron DJ, Tada H, Moscioni AD, Tazelaar J, Fraker DL, Wilson JM, Spitz FR. Intra-arterial delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal cancer. Molecular Therapy 4:29-35, 2001.
  147. Menon C, Iyer M, Prabakaran I, Canter RJ, Lehr SC, Fraker DL. TNF-α downregulates vascular endothelial Flk-1 expression in a human melanoma xenograft model. American Journal of Physiology, 284:H317-H329, 2003.
  148. Lew RJ, Cai X, Fraker D, Furth EE, Ginsberg G. Multifocal malignant gastric GIST – EUS imaging and FNA. Gastrointestinal Endoscopy, 2001 (Submitted)
  149. Bedrosian I, Schlencker J, Spitz FR, Orel SG, Fraker DL, Callans LS, Schnall M, Reynolds C, Czerniecki BJ. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Annals of Surg Oncology 9:457-461, 2002.
  150. Bauer TW, Gutierrez M, Dudrick DJ, Li J, Blair I, Menon C Fraker DL. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Surgery 133: 420-428, 2003.
  151. Canter RJ, Mick R, Hahn SM, Metz JM, Fraker DL. Intra-peritoneal photodynamic therapy (PDT) causes a capillary-leak syndrome. Annals of Surg. Oncology 10:514-524, 2003.
  152. Menon C, Polin GM, Prabakaran I, Hsi A, Cheung C, Culver JP, Pingpank JF, Sehgal CS, Yodh AG, Buerk DG, Fraker DL. An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model. Cancer Research 63:7232-7040, 2003.
  153. Bedrosian I, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, Callans LS, Buzby GP, Rosato EF, Fraker DL, Czerniecki BJ. Change in surgical management of breast cancer patients based on preoperative MR imaging. Cancer 98:468-473, 2003.
  154. Chu AY, LiVolsi VA, Fraker DL, Zhang PJ. Corticomedullary mixed tumor of the adrenal gland with concurrent adrenal myelolipoma. Archives of Pathology & Laboratory Medicine 127:e329-332, 2003.
  155. Kesmodel S, Terhune KP, Canter R, Mandel SJ, Livolsi VA, Baloch ZW, Fraker DL. The diagnostic dilemma of follicular variant of papillary thyroid cancer. Surgery 134:1005-1012, 2003.
  156. Hendren SK, Prabakaran I, Buerk DG, Karakousis G, Feldman M, Spitz FR, Menon C, Fraker DL. Interferon-beta gene therapy improves survival in an immunocompetent mouse model of carcinomatosis. Surgery 135:427-436, 2004.
  157. Wilson JJ, Jones H, Burock M, Smith D, Fraker DL, Metz J, Glatstein E, Hahn SM. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. International Journal of Oncology, 24:711-717, 2004.
  158. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoun J, Fraker DL, El-Diery WS, Spitz FR. Stat1- dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell- surface death signaling pathway by interferon B in human cancer cells. Cancer Research 63, 5299-5307, 2003.
  159. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Annals of Surgery 237:650-657, 2003.
  160. Canter RJ, Zhou R, Kesmodel SB, Zhang Y, Heitjen DF, Glickson JD, Leeper DB, Fraker DL. Meta- iodobenzyl (MIBG) and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma Annals of Surgical Oncology 11:265-273, 2004.
  161. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the use of routine duodenotomy affect rate of cure, development of liver metastases, or survival in patients with
    Zollinger-Ellison syndrome. Annals of Surgery 239:617-625, 2004.
  162. Choi EA, Lei H, Maron DJ, Mick R, Barsoum J, Yu Q, Fraker DL, Wilson JW, Spitz FR. Combined 5-FU/systemic interferon-B gene therapy in long-term results in long-term survival in mice with established colorectal liver metastases. Clinical Cancer Research 10:1535-1544, 2004.
  163. Giorgadze TA, Roy S, Fraker DL, Brooks JSJ, LiVolsi VA. Pathologic Quiz Case: A 49-year-old women with an adrenal mass. Archives of Pathology & Laboratory Medicine 128:1294-1296, 2004.
  164. Kesmodel S, Prabakaran I, Hankey A, Canter R, Menon C, Molnar-Kimber K, Fraker DL. Virus- mediated oncolysis of thyroid cancer by a replication-selective adenovirus driven by a thyroglobulin promoter-enhancer region. Jour. Clinical Endo & Metabolism 90:3440-3448, 2005.
  165. Kesmodel SB, Canter RJ, Terhune KP, Bauer TW, Mick R, Rosato EF, Spitz FR, Fraker DL, Alavi A, Czerniecki BJ. Use of Radiotracer for sentinel lymph node mapping in breast cancer is essential for optimal clinical staging. Clinical Nuclear Medicine 31: 527-533, 2006.
  166. Busch TM, Hahn SM, Wileyto P, Koch CJ, Fraker DL, Zhang P, Putt M, Gleason K, Shin DB, Emanuelle MJ, Jenkins K, Glatstein E, Evans SM. Hypoxia and photofrin uptake in the tumors of patients to receive intraperitoneal photodynamic therapy. Clinical Cancer Research 10:4630-4638, 2004.
  167. Wang HW, Zhu TC, Putt ME, Solonenko, Metz J, Dimofte A, Miles J, Fraker DL, Glatstein E, Hahn SM, Yodh AG. Broadband reflection measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissue before and after Photodynamic therapy. J Biomed Optics 10:1400-1404, 2005.
  168. Carr CE, Cope C, Cohen DL, Fraker DL, Treotola SO. Comparison of sequential versus simultaneous methods of adrenal vein sampling, Journal of Vascular & Interventional Radiology 15:1245-1250, 2004.
  169. Augoutides JG, Abrams M, Berkowitz D, Fraker DL. Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of a massive pheochromocytoma.
    Anesthesiology 101:1022-1024, 2004.
  170. Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR. Mitotic rate as a Predictor of sentinel lymph node positivity in patients with thin melanoma. Annals of Surgical Oncology 12:449-458, 2005.
  171. Evans SM, Fraker DL, Hahn SM, Gleason K, Jenkins WT, Dunphy I, Hwang WT, Zhang P, Collins RC, Koch CJ. Hypoxia and clinical outcome in human soft tissue sarcomas IJROBP, 64:922-927, 2006.
  172. Choe R, Corlu A, Lee K, Durduran T, Konecky SD, Grosicka-Koptyra M, Arridge SR, Czerniecki BJ, Fraker DL, DeMichele A, Chance B, Rosen MA, Yodh AG. Diffuse optical tomography of breast Cancer during neoadjuvant chemotherapy: a case study with comparison to MRI Medical Physics 32:1128-1139, 2005.
  173. Downes KJ, Glatt BJ, Kanchwala SK, Mick R, Fraker DL, Fox KR, Solin LJ, Bucky LP, Czerniecki BJ. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer 103:906-913, 2005.
  174. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, and Bernhard EJ. Pancreatic Cancer Cell Radiation Survival and Prenyltransferase iInhibition: The Role of K-Ras. Cancer Research 65:8433-8441, 2005.
  175. Shah JN, Fraker DL, Guerry D, Feldman M, Kochman ML. EUS-FNA: Melanoma seeding of biopsy track. Gastrointestinal Endoscopy. 59:923-924, 2004.
  176. Rapaport-Kelz R, Gimotty PA, Polsky D, Norman S, Fraker DL, DeMichele A. Morbidity and Mortality of Colorectal Operations Differs by Insurance Status. Cancer 101:2187-2194, 2004.
  177. Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Botbyl JD, Elder DE, Elenitsas R, Ming ME, Schuchter L, Guerry D, and Gimotty PA and. Predicting sentinel lymph node status in AJCC Stage I and II Primary Cutaneous Melanoma Cancer 107:2436-2445, 2006.
  178. Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR. Predictors of regional nodal disease in patients with thin melanomas Annals of Surgical Oncology 13:533-541, 2006.
  179. Menon C, Gharty A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Annals of Surgery 244:781-791, 2006.
  180. Lei H, Furlong PJ, Ra JH, Mullins D,Cantor R, Fraker DL, Spitz FR. AKT activation and response to Interferon-beta in human cancer cells. Cancer Biology & Therapy 4:709-715, 2006.
  181. Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, Zhu T, Rodriguez C, Dimofte A, Spitz FR, Putt M, Rubin SC, Menon C, Wang HW, Shin D, Yodh A, Glatstein E. A Phase II trial of Intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and Sarcomatosis. Clinical Cancer Research 12:2517-2525, 2006.
  182. Lee LS, Canter RJ, Fraker DL. Intraoperative jugular venous sampling aids detection of undescended parathyroid adenomas. World Journal of Surgery 30:620-623, 2006.
  183. Canter RJ, Kesmodel SB, Heitjan DF, Veeramachaneni NK, Mokadam NA, Drebin JA, Fraker DL. Suppression of Beta-catenin by antisense oligomers augments tumor response to isolated limb Perfusion in a rodent model of adenomatous polyposis coli (APC)- mutant cancer. Annals of Surgical Oncology 12:1-11, 2005.
  184. Menon C, Bauer TW, Kelley ST, Raz DJ, Bleier JI, Patel K, Steele K, Prabakaran I, Shifrin A, Buerk DG, Sehgal CM Fraker DL. Tumoricidal activity of high-dose tumor necrosis factor Alpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. International Journal of Cancer 123:464-475, 2008
  185. Kreisel D, Krupnick AS, Engels FH, Furth EE, Fraker DL. Hepatic lobectomy for metastatic Merkel cell carcinoma: A case report, (manuscript in preparation).
  186. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schucter L, Spitz FR, Czerniecki BJ, Guerry D. Identification of high risk patients among those diagnosed with thin invasive cutaneous melanomas. Journal of Clinical Oncology 25:1129-1134, 2007.
  187. Cornett WR, Fraker DL, Petersen RP, McCall LM, Ross MI, Briele HA, Boddie AW, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL, Chadarem V, Herndon JE, Tyler DS. A prospective randomized Multi-center trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan Plus tumor necrosis factor: three month follow up for ACOSOG Z0020. Journal of Clinical Oncology, 24:4196-4201, 2006.
  188. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr D, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Annals of Surgery 244:410-419, 2006.
  189. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Mick R, Menon C, Glatstein E, Fraker DL, Busch TM. Photofrin uptake in the tumor and normal tissues of patients receiving intra-peritoneal Photodynamic therapy. Clinical Cancer Research 12:5464-5470, 2006.
  190. Fraker DL. Commentary on “Remedial parathyroid surgery: Changing Trends in 130 consecutive cases. Nature Clinical Practice Endocrinology & Metabolism 3:330-331, 2007.
  191. Karakousis GC, Han D, Roses RE, Neemani D, Karmachaya J, Rapaport-Kelz R, Fraker DL. Interpretation of intra-operative PTH changes in patients with multi-gland primary hyperparathyroidism. Surgery 142:845-850, 2007.
  192. Norton JA, Venzon DJ, Alexander HR, Fraker DL, Libutti SK, Marx SJ, Gibril F, Jensen RT. Prospective study of surgery for primary hyperparathyroidism in multiple endocrine neoplasia Type 1, and Zollinger-Ellison syndrome: Longterm outcome of a more virulent form of HPT. Annals of Surgery 247:501-510, 2008.
  193. Karakousis, GC, Gimotty, PA, Czerniecki, BJ, Elder, DE, Elenitas R, Ming ME, Fraker DL, Spitz FR. Regional nodal metstatic disease is the strong predictor of survival in patients with vertical growth Phase metastases: A case for sentinel lymph node biopsies in these patients. Annals of Surgical Oncology 14: 596-603, 2007.
  194. Cohen DL, Fraker DL, Townsend RR. Lack of symptoms in patients with histologic evidence Of pheochromocytoma: a diagnostic challenge. New York Academy of Sciences 1073: 47-51, 2006.
  195. Tchou J, Greshock J, Bergey MR, Sonnad SS, Sargen M, Weinstein S, Czerniecki BJ, Boraas M Fraker DL, Rosato E, Fox K, Weber B, Solin LJ. Method of primary tumor detection as a risk factor for local and distant recurrence after breast conservation treatment for early stage breast cancer. Clinical Breast Cancer 8:143-148, 2008.
  196. Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker DL, Hughes MS, Jensen RT, Marx SJ, Libutti SK. The utility Of routine transcvervical thymectomy for multiple endocrine neolplasia 1 related hyperpara- Thyroidism. Surgery 144:878-884, 2008.
  197. Murashima M, Trerotola O, Fraker DL, Han D, Townsend R, Cohen DL. Change in the pattern of adrenal vein sampling over time in patients with primary hyperaldosteronism. Journal of Human Hypertension 23:292-294, 2009.
  198. Alexander HR, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH . Analysis of factors associated with outcome in patients undergoing isolated Hepatic perfusion for unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16: 1852-1859, 2009.
  199. Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, Demichelle A, Chance B, Arridge SR, Schweiger M, Culver J, Schnall MD, Putt ME, Rosen MA, Yodh AG. Differentiation of benign and malignant breast tumors by in vivo three- Dimensional parallel plate diffuse optical tomography. Journal of Biomedical Optics 14:1-18, 2009.
  200. Murashima M, Trerotola SO, Fraker DL, Han D, Townsend RR, Cohen DL. Adrenal vein sampling For primary aldosteronism and clinical outcomes after unilateral adrenalectomy: a single-center Experience. Journal of Clinical Hypertension 11:316-323, 2009.
  201. Fraker DL, Harsano H, Lewis R. Minimally invasive parathyroidectomy: Benefits and requirements of localization, diagnosis, and intra-operative PTH monitoring. Long term results.
    World J. Surg 33:2256-2265, 2009.
  202. Huang JH, Lee FS, Pasha TL, Sammel MD, Karakousis G, Xu G, Fraker DL, Zhang PJ. Analysis Of HIF-1 and its regulator, PHD2, in retroperitoneal sarcomas: Clinico-pathologic implications. Cancer Biology & Therapy 9:4, 1-9, 2010.
  203. Alexander HR, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Sovner P, Beresneva TH.Analysis of factors influencing outcome in patients with in transit malignant melanoma undergoing ILP using modern treatment parameters. Jour. Clin Oncol. 28:114-118, 2010.
  204. Albert M, Wheatley M, Sun WJ, Haller D, Fraker DL, Tuite, C, Mondschien JI, Stavropoulos W, Soulen MC. Chemoembolization of colorectal metastases with cisplatin, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol. Cancer, in press, 2010.
  205. Furstenau DK, Mitra N, Wan F, Lewis R, Feldman MD, Fraker DL, Guvakova MA. Ras-related Protein 1 and the insulin-like growth factor type 1 receptor are associated with risk of progression in Patients diagnosed with carcinoma in situ. Breast Cancer Research and Treatment, in press, 2010.
  206. Lewis R, Ebebe K, Han D, Fraker DL. Primary Hyperparathyroidism with Negative Preoperative Imaging still most commonly caused by a solitary parathyroid adenoma. Submitted to Annals Of Surgical Oncology, (March 2010).
  207. Lewis R, Ebebe K, Han D, Cohen DL, Fraker DL. Pheochromocytoma: Increased Incidence of Asymptomatic Presentation. Submitted to the Annals of Surgical Oncology (March 2010).
  208. Han D, Lewis R, Kelz RR, Fraker DL. Fine Needle Aspiration Cytology for Nodular Thyroid Disease: Room for Improvement. Submitted to the Annals of Surgical Oncology (March 2010).
  209. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker DL, Olthoff K, Shaked A, Rilling W, Soulen MC. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatin, adriamycin, Mitomycin C, ethiodol, and polyvinyl alcohol. (submitted to Radiology 2010).
  210. Trerotola SO, Smoger DL, Cohen DL, Fraker DL. The inferior accessory hepatic vein: An Anatomic landmark in adrenal vein sampling (submitted Radiology 2010).
  211. Shah PK, Shah KK, Karakousis GC, Reinke CE, Kelz RR, and Fraker, DL.  Regional Recurrence
    After Lymphadenectomy for Clinically Evident Lymph Node Metastases from Papillary Thyroid
    Cancer:  A Cohort Study.  Annals of Surgical Oncology 19:1453-1459, 2012.
  212. Prabakaran I, Grau JR, Lewis R, Fraker DL, and Guvakova MA.  Rap2A is upregulated in invasive
    Cells dissected from follicular thyroid cancer.   Journal of Thyroid Research (in press 2011)
  213. Reinke CE, Hadler RA, Karakousis GC, Fraker DL and Kelz RR.  Does the presence of thyroid  
    Cancer increase the risk of thromboembolism in patients undergoing thyroidectomy?  Surgery
    150:1275-1285, 2011.
  214. Reinke, CE, Karakousis GC, Hadler RA, Drebin JA, Fraker DL, and Kelz RR.  Incidence of
    Thromboembolism in patients undergoing surgical treatment for malignancy by type of neoplasm:      
    An analysis of ACS-NSQIP data from 2005-2010.   Surgery  152:186-192, 2012.
  215. Yang RL, Freeman K, Reinke CE, Fraker DL, Karakousis GC, Kelz RR, and Doyle A.  Tertiary
    Hyperparathyroidism in kidney transplant recipients:  Characteristics of patients selected for
    different treatment strategies.   Transplantation 94:70-76, 2012.
  216. Lewis, R, Drebin JA, Callery MP, Fraker, DL, Kent TS, Gates J, Vollmer CM.  A contemporary
    Analysis of survival for resected pancreatic ductal adenocarcinoma  HPB 15:49-60,  2013
  217. Norton,JA, Fraker DL, Alexander HR, and Jensen RT. Value of surgery in patients with negative
    Imaging and sporadic Zollinger-Ellison syndrome.  Annals of Surgery 256:509-517, 2012.
  218. Singh MH, Fraker DL, and Metz DC.  Importance of Surveillance for Multiple Endocrine Neoplasia-1
    and Surgery in patients with Sporadic Zollinger-Ellison Syndrome. Clinical Gastroenterology      
    and Hepatology,  10:1262-1269, 2012.
  219. Burshteyn M, Cohen DL, Fraker DL, and Trerotola SO.  Adrenal venous sampling in chronic kidney
    disease patients.  J Vasc Interv Radiol 24: 726-733, 2013.
  220. Bai S, Livolsi VA, Fraker DL, and Bing Z.   Water clear parathyroid adenoma: A report of two cases
    and a literature review.  Endocrine Pathology 23:196-200, 2012.
  221. Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL.  Inherited mutations in pheochromo-
    cytoma and paraganglioma: why all patients should be offered genetic testing.  Ann Surg Oncol
    20:1444-1450, 2013.
  222. Bartlett EK, Roses RE, Gupta M,. Shah PK, Shah KK, Zaheer S, Wachtel H, Kelz RR, Karakousis
    GC, Fraker DL.  Surgery for metastatic neuroendocrine tumors with occult primaries.  J. Surg Res
    184:221-227, 2013.
  223. Bartlett EK, Meise C, Bansai N, Fischer JP, Low DW, Czerniecki BJ, Roses RE, Fraker DL, Kelz RR,
    Karakousis GC.  Sartorius transposition during inguinal lymphadenectomy for melanoma.  J Surg
    Res.  184:209-215, 2013.
  224. Bartlett EK, Meise C, Roses RE, Fraker DL, Kelz RR, Karakousis GC.    Morbidity and mortality of
    cytoreduction with intraperitoneal chemotherapy:  Outcomes from the ACS NSQIOP database.
    Ann Surg Oncol 21:1494-1500, 2014.
  225. Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schucter L, Xu X, Elder DE, Ming M,
    Elenitsas R, Guerry D, Kelz RR Czerniecki BJ, Fraker DL, Karakousis GC.  Clark level risk stratifies
    Patients with mitogenic thin melanomas for sentinel lymph node biopsy.  Ann Surg Oncol 21:643-649
    2014.
  226. Nasrallah, MP, Fraker DL, Livolsi VA. Parathyroid carcinoma in the setting of tertiary hyperpara-
    Thyroidism after a renal transplant.  Endocrine Pathology  (in press, 2014)
  227. Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu, X, Ming ME,
    Schucter LM, Fraker DL, Czerniecki BJ, Karakuosis GC.  Local immune response predicts survival
    In patients with thick (T4) melanomas.  Ann Surg Oncology (in press, 2014).
  228. Bartlett EK, Roses RE, Meise C, Fraker DL, Kelz RR, Karakousis GC.   Pre-operative radiation for
    retroperitoneal sarcoma is not associated with increased early post-operative morbidity.  Journal of
    Surgical Oncology 109:606-611, 2014
  229. Bartlett EK, Gupta M, Datta J, Gimotty PA, Guerry D, Xu S, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.  Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy.  Ann Surg Oncol 21(3):1016-23, 2014.
  230. Surrey Sadri N, Surrey LF, Fraker DL, Zhang PJ.  Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation.  Virchows Arch 464(4):505-9, 2014.
  231. Bartlett EK, Wachtel H, Fraker DL, Vollmer CM, Drebin JA, Kelz  RR, Karakousis GC, Roses RE.  Surgical palliation for pancreatic malignancy: Practice patterns and predictors of morbidity and mortality.  J Gastrointest Surg  Mar 27, 2014.
  232. Kelz RR, Fraker DL.  Metastatic carcinoid: Don’t forget the surgical consultation.  Ann Surg Oncol (in press, 2014).
  233. Wachtel H, Bartlett EK, Kelz RR, Cerullo I, Karakousis GC, Fraker DL.  Primary hyperparathyroidism with negative imaging: A significant clinical problem. Ann Surg (in press, 2014).
  234. Wachtel H, Cerullo I, Bartlett EK, Kelz RR, Cohen DL, Karakousis GC, Roses RE, Fraker DL.  Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism.  Surgery (in press, 2014).
  235. Bartlett EK, Choudhury R, Roses RE, Fraker DL, Kelz RR, Karakousis GC.  Intraperitoneal chemotherapy at the time of surgery is not associated with increased 30-day morbidity and mortality following colorectal resection.  Ann Surg Oncol (in press, 2014).
  236. Datta J, Lewis RS, Mamtani R, Stripp D, Kelz RR, Drebin JA, Fraker DL, Karakousis GC, Roses RE.  Implications of inadequate lymph node staging in a resectable gastric cancer: A contemporary analysis using the National Cancer Data Base.  Cancer (in press, 2014).
  237. Kuo LE, Wachtel H, Kelz RR, Fraker DL.  An unusual caser of hypercalcemic crisis.  Surgery (Submitted 2014).
  238. Wachtel H, Cerullo I, Bartlett EK, Roses RE, Cohen DL, Kelz RR, Karakousis GC, Fraker DL.  Clinicopathologic characteristics of incidentally identified pheochromocytoma.  Ann Surg Oncol (Submitted 2014).
  239. Bartlett EK, Hoffman RL, Karakousis GC, Roses RE, Fraker DL, Morris JB, Kelz RR.  Hernia repair in the decompensated cirrhotic patient.  J Surg Res (Submitted 2014)
  240. Bartlett EK, Wachtel H, Fraker DL, Vollmer CM, Drebin JA, Kelz RR, Karakousis GC, Roses RE.  Surical palliation for pancreatic malignancy: Practice patterns and predictors of morbidity and mortality.  J Gastrointest Surg (Submitted 2014).
  241. Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC.  Morbidity and mortality after total gastrectomy for gastric malignancy.  Surgery (Submitted 2014).
  242. Kuo LE, Wachtel H, Fraker DL, Kelz R.  Parathyroidectomy in dialysis patients.  J Surg Res (in press 2014)
  243. Kuo LE, Wachtel H, Fraker DL, Kelz R. Reoperative parathyroidectomy: Who is at risk and what is the risk?  J Surg Res (in press 2014)
  244. Trerotola SO, Asmar M, Yan Y, Fraker DL, Cohen D.  Failure mode analysis in adrenal vein sampling.   Journal of Vascular Interventional Radiology, (submitted 2014).
  245. Wachtel H, Gupta M, Bartlett EK, Jackson BM, Kelz RR, Karakousis GC, Fraker DL, Roses R.  Operative outcomes after resection of leiomyosarcoma of the inferior vena cava: A pooled data analysis of 377 cases.  Ann Surg Oncol (submitted 2014).
  246. Wachtel H, Cerullo I, Bartlett EK, Fishbein L, Roses RE, Fraker DL, Cohen DL.  Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma.  J Clin Endocrinol and Metabol (submitted 2014).
  247. Farquhar DR, Wachtel H, Cerullo I, Bartlett EK, Kelz RR, Karakousis GC, Fraker DL.  Incidental cancer in surgically treated benign goiter.   Ann Surg Oncol (submitted 2014).
  248. Wachtel H, Gupta M, Cerullo I, Bartlett EK, Kelz RR, Karakousis GC, Fraker DL.  Early onset primary hyperparathyroidism: Characterization and management.  J Clin Endocrinol and Metabol (submitted 2014).
  249. Fishbein L, Khare S, Wubbenhurst B, DeSloover D, D’andrea K, Cho N, Greenberg R, Else T, Montone K, Livolsi V, Fraker DL, Cohen DL, Daber R, Nathanson KL.  Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.  Nature Genetics (submitted 2014).
Chapters and Reviews
  1. Norton JA and Fraker DL. Malignant neoplasms: the role of specific serum tests in the diagnosis, management, and evaluation of recurrence, In: Textbook of Surgery: Update 2, Ed. Sabiston, D.C., W.B. Saunders, Philadelphia, pp. 19-37, 1989.
  2. Fraker DL. Blood gases and acid-base disorders, In: Clinicians Pocket Reference, 6th Edition; ed. Gomella, L.G. Appleton & Lange, East Norwalk, CT. pp. 127-134, 1989.
  3. Fraker DL. Fluids and electrolytes, In: Clinicians Pocket Reference. 6th Edition, ed. Gomella, L.G. Appleton & Lange, East Norwalk, CT, pp. 127-134, 1989.
  4. Fraker DL and Norton JA. The role of surgery in the management of islet cell tumors. Gastroenterology Clin. of N. Am. 18: 805-830, 1989.
  5. Norton JA and Fraker DL. Tumor markers. In: Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 14th edition, ed: Sabiston, D.C., W.B. Saunders, Philadelphia, pp. 491-509, 1991.
  6. Norton JA and Fraker DL. Tumor markers. In: The Essentials of Surgery, 2nd edition, ed: Sabiston, D.C., W.B. Sanders, Philadelphia, 237-245, 1991.
  7. Fraker DL, Alexander HR, Norton JA. Biologic therapy of sepsis: the role of antibodies to endotoxin and tumor necrosis factor, and the interleukin-1 receptor antagonist. In: Biologic Therapy of Cancer, Principles and Practice. PPO Updates. DeVita VT,Jr., Hellman,S., Rosenberg,SA, eds. Lippincott, Philadelphia, 2: 1-13, 1992.
  8. Norton JA and Fraker DL. Tumor markers. Textbook of Surgery: Pocket Companion ed.: Sabiston, D.C., Lyerly, H.K. W.B. Saunders, Philadelphia, 232-242, 1992.
  9. Obstetrics and Gynecology on Call, eds: Horowitz, I.R., Gomella, A.T. Appleton & Lange, Norwalk, Ct. Fraker, D.L., contributor, 1993.
  10. Norton JA, Doherty GM, Fraker DL. Surgery for Endocrine Tumors of the Pancreas. In: The Pancreas: Biology, Pathbiology and Disease. VLW Go, et al (Eds) 2nd ed. Raven Press, New York, 1009-1027, 1993.
  11. Fraker DL, Alexander HR. The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. In: Principle and Practice of Oncology. PPO Updates. DeVita, V., Hellman, S., Rosenberg, S., eds. J.B. Lippincott, Philadelphia, 7: 1-10, 1993.
  12. Fraker DL, Norton JA. The role of tumor necrosis factor in the toxicity and the antineoplastic activity of interleukin-2 immunotherapy. In: Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basal Karger, 1993; pp 221-225.
  13. Fraker DL, Norton JA. Controversies in surgical therapy for apudomas. Semin Surg Oncol 9: 437-442, 1993.
  14. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: Important Advances in Oncology. DeVita, V., Hellman, S., Rosenberg, S.A. eds, Lippincott, Philadelphia, 179-192, 1994.
  15. Fraker DL, Alexander HR, Pass HI. Biologic therapy with tumor necrosis factor: Clinical applications by systemic and regional administration. In: Biologic Therapy of Cancer, 2nd ed. eds., DeVita, V., Hellman, S., Rosenberg, S.A. Lippincott, Philadelphia, 329-346, 1995.
  16. Fraker DL, Norton JA. Endocrine Pancreas. In: Clinical Surgery, Davis J, ed. 2nd ed. Mosby, St. Louis, 2398-2421, 1995.
  17. Fraker DL and Alexander HR. The surgical approach to endocrine tumors of the pancreas. Semin Gastrointest Dis, 6:102-113, 1995.
  18. Fraker DL. Factors that predispose to human thyroid neoplasia. Surg Clin N Am, 75: 365-375, 1995.
  19. Alexander HR, Buell JF, Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion (CHPP) for the treatment of peritoneal carcinomatosis. In: Principal and Practice of Oncology. PPO Updates. Eds. DeVita, V., Hellman, S., Rosenberg, S., J.B. Lippincott, Philadelphia. 9: 1-9, 1995.
  20. Fraker DL. Book review of Cancer Surgery, ed. McKenna, R.J. and Murphy, G.P. Lippincott, Philadelphia, PA. Oncology, 9:410, 1995.
  21. Yang JC, Fraker DL, Thom AK, Pass HI, Rosenberg SA. Isolation perfusion with tumor necrosis factor-alpha, interferon-gamma, and hyperthermia in the treatment of localized and metastatic cancer. Recent Results in Cancer Research 138:161-6, 1995.
  22. Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Seminars in Surgical Oncology 12(6):416-28, 1996.
  23. Norton JA and Fraker DL. Tumor markers. In: Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 15th edition, ed: Sabiston, D.C., W.B. Saunders, Philadelphia, In Press, 1996.
  24. Norton JA and Fraker DL. Tumor markers. Textbook of Surgery: Pocket Companion, 2nd ed.: Sabiston, D.C., Lyerly, H.K. W.B. Saunders, Philadelphia, In Press, 1996.
  25. Fraker DL, Jensen RT. Pancreatic endocrine tumors. In: Cancer: Principles and Practice of Oncology, 5th Edition. Eds. DeVita V, Rosenberg SA, Hellman S. JB Lippincott Co., Philadelphia, pp. 1678-1703, 1996.
  26. Fraker DL. Parathyroid cancer. In: Cancer: Principles and Practice of Oncology, 5th Edition. Eds. DeVita V, Rosenberg SA, Hellman S. JB Lippincott Co., Philadelphia, pp. 1652-1658, 1996.
  27. Fraker DL, Skarulis M, LiVolsi,V. Thyroid cancer. In: Cancer: Principles and Practice of Oncology, 5th Edition. Eds. DeVita V, Rosenberg SA, Hellman S. JB Lippincott Co., pp. 1629-1651, 1996.
  28. Alexander HR, Fraker DL. Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. In: Peritoneal Carcinomatosis: Drugs and Diseases Ed. Sugarbaker P. Kluwer Academic Publishers, Boston, pp. 41-50, 1996.
  29. Fraker DL. Factors which predispose to thyroid neoplasia, In: Textbook of Endocrine Surgery. Eds., Clark, O.H.,Duh, Q.Y., Siperstein, A. W.B. Saunders, Philadelphia, 190-197, 1997.
  30. Fraker DL, Alexander HR. Isolated perfusion of the liver. Regional Therapy of Advanced Cancer. Eds., Lotze, M.T., Rubin, J.T. Lippincott-Raven, Philadelphia. 141-150, 1997.
  31. Alexander HR, Fraker DL. Shunting procedures for malignant ascites and pleural effusions. In: Regional Therapy of Advanced Cancer. Eds. Lotze, M.T., Rubin, J.R. Lippincott-Raven, Philadelphia. 271-280, 1997.
  32. Fraker DL, Coit D. Isolated perfusion of extremity tumors. In: Regional Therapy of Advanced Cancer. Eds. Lotze, M.T., Rubin, J.R. Lippincott-Raven, Philadelphia, 333-349, 1997.
  33. Fraker DL. Surgical issues in the management of melanoma. Current Opinion in Oncology 9:183-188, 1997.
  34. Fraker DL. Hyperthermic Regional Perfusion for Melanoma of the Limbs. In: Cutaneous Melanoma, 3rd Edition. Eds. Balch CM, Houghton AN, Sober AT, Soong SJ. Quality Medical Publishing, St. Louis, MO, pp. 281-300, 1998.
  35. Fraker DL. Hyperthermic Regional Perfusion for Melanoma and Sarcoma of the Limbs. Current Problems in Surgery 1999, 36(11):841-908.
  36. Fraker DL, Skarulis M. Thyroid and Parathyroid Cancer In: Integrated Cancer Management. Torosian MH, ed., Marcel Dekker, Inc, New York, pp. 322-344, 2000.
  37. Hahn SM, Sindelar WF, Delaney TF, Rubin SC, Fraker DL, His RA, Glatstein E. Intraperitoneal PDT for the Treatment of Recurrent Ovarian Cancer. Photomedicine in Gynecology and Reproduction, eds., P Wyss, Y Tadir, BJ Tromberg, U Haller, Philadelphia, PA, 285-295, 2000.
  38. Schuchter LM, Haluska F, Fraker DL, Elenitsas R. Skin: Malignant Melanoma. In: Clinical Oncology. Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds., Churchill Livingstone, New York, pp. 1317-1350, 2000.
  39. Fraker DL. Update on Management of Parathyroid Tumors. In: Current Opinion in Oncology. 2000, 12:41-48.
  40. Schuchter L, Green R, Fraker DL. Primary and Metastatic Diseases in Malignant Melanoma of the Gastrointestinal Tract. In: Current Opinion in Oncology, Volume 12. Lippincott Williams & Wilkins, Philadelphia 2000, pp 181-5.
  41. Bauer TW, Maron D, Choi EA, Fraker DL. Thyroid, Parathyroid, and Adrenal Glands. In: The Surgical Review, Kreisel D, Krupnick AS, Kaiser LR (eds), Lippincott, Williams & Wilkins, Philadelphia, PA 2000.
  42. Fraker DL, Skarulis M, Livolsi V. Thyroid Cancer. In: Cancer: Principles and Practice of Oncology, 6th Edition. Eds. DeVita V, Rosenberg SA, Hellman S. JB Lippincott Co., 2001, pp. 1740-1762.
  43. Fraker DL. Parathyroid Cancer. In: Cancer: Principles and Practice of Oncology, 6th Edition. Eds. DeVita V, Rosenberg SA, Hellman S. JB Lippincott Co., 2001 , pp. 1763-1769.
  44. Fraker DL. Regional Therapies of Cancer. In: Surgery: Scientific Basis and Current Practice. Norton, Bollinger, Chang, Lowry, Mulvihill, Pass and Thompson, eds. Springer-Verlag, New York, 2001, pp. 1863-1880.
  45. Fraker DL. Diagnostic Testing and Clinical Decision Making. In: Surgical Endocrinology. Doherty GM, Skogseid (eds) JP Lippincott, Williams & Wilkins, Philadelphia,PA, 2001,pp. 3-6.
  46. Fraker DL. Radiofrequency ablation of colorectal metastases to the liver. In: Multimodality Management, Saltz L, (ed), Humana Press, Totowa, NJ, pp 437-54, 2002.
  47. Fraker DL. The Spleen. In: Surgery: Scientific Principles and Practice, 3rd edition. Greenfield L (ed), Lippincott Williams and Wilkins, Philadelphia, PA pp 1205-1232, 2001.
  48. Fraker DL, Soulen M. Regional therapy of hepatic metastases. Hematology & Oncology Clinics of North America 16:947-967, 2002.
  49. Fraker DL. Hyperthyroidism: Medical and Surgical Management” in Endocrine Surgery of the Head and Neck, Pellitieri P and McCaffrey (eds),Delmar, Clifton Park, NY, pp 235-252, 2003.
  50. Fraker DL. Invited commentary on “Current approaches to the treatment of well-differentiated thyroid cancer”. Oncology 16: 318-324, 2002.
  51. Doherty GM, Fraker DL, Hohn DC. Spleen. In: Current Surgical Diagnosis and Treatment. 11th Way L.W, Doherty GM, eds. Lange/Mcgraw-Hill, New York, NY. Pp 652-667, 2003.
  52. Fraker DL, Eggermont, AE.. Hyperthermic Regional Perfusion for Melanoma of the Limbs. In: Cutaneous Melanoma, 4th Edition. Eds. Balch CM, Houghton AN, Sober AT, Soong SJ. Quality Medical Publishing, St. Louis, MO, pp. 473-494, 2003.
  53. Fraker, DL. “Melanoma and Skin Tumors”, Section Editor, in Current Treatment Options in Oncology, June, 2003.
  54. Fraker DL. “Combination of Radiofrequency Ablation and Intra-arterial chemotherapy for metastatic cancer in the liver”, in Radiofrequency Ablation for Cancer, Eds Ellis LM, Curley SA, Tanabe KK, Springer-Verlag, New York City, NY, pp 47-66, 2004.
  55. Fraker DL. Parathyroid Cancer. In: Cancer: Principles and Practice of Oncology, 7th Edition. Eds. DeVita V, Rosenberg SA, Hellman S. JB Lippincott Co., pp 1521-1528, 2005.
  56. Fraker DL. “Management of In Transit Melanoma of the Extremity with Isolated Limb Perfusion” in Current Treatment Options in Oncology, 5:173-184, 2004.
  57. Fraker, DL. “Melanoma and Skin Tumors”, Section Editor, in Current Treatment Options in Oncology, June, 2004.
  58. Menon CK, Fraker DL. “Tumor Oxygenation Status as a Prognostic Marker” an invite Mini-review in Cancer Letters 221:225-235, 2005.
  59. Fraker DL. The Spleen. In: Surgery: Scientific Principles and Practice, 4th edition. Mulholland M Lillemoe K (eds), Lippincott Williams and Wilkins, Philadelphia, PA pp. 1222-1250, 2005.
  60. Doherty GM, Fraker DL. Spleen. In: Current Surgical Diagnosis and Treatment. 12th edition Way L.W, Doherty GM, eds. Lange/Mcgraw-Hill, New York, NY (in press, 2005).
  61. Fraker, DL. “Melanoma and Skin Tumors”, Section Editor, in Current Treatment Options in Oncology, June, 2005.
  62. Rapaport-Kelz R, Fraker DL. Factors which predispose to thyroid neoplasia, In: Textbook of Endocrine Surgery. 2nd edition Eds., Clark, O.H.,Duh, Q.Y., Siperstein, A. Elsevier Saunders, Philadelphia, pp 240-247, 2005.
  63. Fraker DL. “Recurrent in-transit Melanoma” in Clinical Scenarios in Surgical Oncology, Khatri VP, ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp 307-311, 2005.
  64. Karakousis GC, Rapaport-Kelz R, Fraker DL. “Thyroid, Parathyroid, and Adrenal Glands”, in The Surgical Review: An Integrated Basic and Clinical Science Study Guide. 2nd edition, Lippincott Williams and And Wilkins, Philadelphia, PA. pp 458-479, 2005.
  65. Fraker DL.Regional Therapies of Cancer. In Surgery: Scientific Basis and Current Practice. 2nd ed Norton JA, Barie PS,Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, Pass HI and Thompson RW. (eds) Springer-Verlag, New York, pp 2151-2174, 2008.
  66. Fraker DL. Parathyroid Cancer. In: Cancer: Principles and Practice of Oncology, 8th Edition. Eds. DeVita V, Rosenberg SA, Lawrence T. JB Lippincott Co pp 1682-1689, 2007.
  67. Fraker DL. Neoplasms of the Adrenal Gland. In: Cancer: Principles and Practice of Oncology, 7th Edition. Eds. DeVita V, Rosenberg SA, Lawrence T. JB Lippincott Co pp1702-1720, 2007.
  68. Fraker DL. Thyroid Cancer. In Textbook of Surgical Oncology, Beauchamp D ed. Informa Healthcare, London UK. pp 339-352, 2007.
  69. Alexander HR, Fraker DL, Eggermont, AE.. Hyperthermic Regional Perfusion for Melanoma of the Limbs in Cutaneous Melanoma 5th edition. Eds Balch CM, Houghton AN, Sober AT, Soong SJ. Quality Medical Publishing St. Louis (in press, 2009).
  70. Karakousis GC, Fraker DL. Thyroidectomy and Parathyroidectomy In Gowned and Gloved Surgery: Introduction to Common Procedures. Kanchwala S, Paulson , Roses R (eds) Elsevier, Philadelphia, (in press), 2008.
  71. Doherty GM, Fraker DL. Spleen. In: Current Surgical Diagnosis and Treatment. 13th edition , Doherty GM, eds. Lange/Mcgraw-Hill, New York, NY pp 597-614, 2010.
  72. Fraker DL. The Spleen. In: Surgery: Scientific Principles and Practice,4th edition. Mulholland M Lillemoe K (eds), Lippincott Williams and Wilkins, Philadelphia, PA (submitted) 2010.
  73. Karakousis GC, Rapaport-Kelz R, Fraker DL. “Thyroid, Parathyroid, and Adrenal Glands”, in The Surgical Review: An Integrated Basic and Clinical Science Study Guide. 3rd edition Porrett PM, Frederick JR, Roses RE and Kaider LR Lippincott Williams and Wilkins, Philadelphia, PA pp 233-251, 2010.
  74. Karakousis GC and Fraker DL.  Isolated Limb Perfusion (ILP) and Isolated limb infusion (ILI) for
    Locally Advanced Malignant Melanoma.  Goodman MD, ed in Regional Therapeutics for Advanced
    Malignancies.  Jaypee, New Dehli, India, pp 83-91, 2012..
  75. Fraker DL.  “Parathyroid:  Adenoma, Primary/Secondary Hyperparathyroidism.   Audio Digest
    General Surgery Board Review.   Steven D. Wexner, senior editor, October 2013.
  76. Kelz R, Fraker DL.  Factors Which Predispose to Thyroid Neoplasia. In: Textbook of Endocrine Surgery, 3rd Edition. Eds Clark OH, Duh QY, Siperstein A.  Elsevier Saunders. In press. 2014.
  77. Fraker DL. Operative Approach to Insulinoma:. In: Operative Techniques in Surgery. Eds: Sabel MS and Mulhollan M.  Lippincott, Williams & Wikins, 2014.
  78. Fraker DL.  Posterior Adrenalectomy.  In: Atlas of Endocrine Surgery. Eds: Howe JR.  Springer, 2014.
  79. Roses R, Fraker DL.  Gastroparesis and Biliary Reflux.  In: Gastrointestinal Surgery: Management of Complex Perioperative Complications.  Eds: Pawlik, Matthel and Merchant.  Springer, 2014.
Books
  1. Surgery on Call, eds: Gomella, L.G. and Lefor, A.T.; Assoc. eds. Fraker DL and Wiebke, E.A. Appleton & Lange, Norwalk, CT. 1990.
  2. Surgery On Call, 2nd Edition, eds: Gomella,L.G. and Lefor,A.T.; Assoc. eds. Fraker, D.L. and Wiebke,E.A. Appleton & Lange, Norwalk, CT 1996.
  3. Clinician's Pocket Reference, 8th edition, ed.: Gomella LG; Contributor: Fraker DL. Appleton and Lange, Norwalk, CT, 1997.
  4. Internal Medicine On Call, Second Edition, eds: Haist SA, Robbins JB, and Gomella LG. Contributor: Fraker DL. Appleton and Lange, Norwalk, CT, 1997.
  5. Surgery On Call, 3rd Edition, eds: Gomella,L.G. and Lefor,A.T.; Assoc. eds. Fraker, D.L. and Wiebke,E.A. Appleton & Lange, Norwalk, CT 2001.
  6. Surgery On Call, 4th Edition, eds: Gomella,L.G. and Lefor,A.T.; Assoc. eds. Fraker, D.L. Wiebke,E.A, and Soukiasian HJ. Appleton & Lange, Norwalk, CT 2001.
 
Awards
2012 - 2013 William Inouye Award for Outstanding Faculty
From the graduating Chief Residents
 
2013 Top Doctor, General Surgery, Philadelphia Magazine
 
2012 Top Doctor, General Surgery, Philadelphia Magazine
 
2011 - 2012 William Inouye Award for Outstanding Faculty (from the graduating Chief Residents)
 
2011 Top Doctor, General Surgery, Philadelphia Magazine
 
2010 Top Doctor, General Surgery, Philadelphia Magazine
 
2009 Top Doctor, General Surgery, Philadelphia Magazine
 
2008 Top Doctor, General Surgery, Philadelphia Magazine
 
2007 - 2008 Penn Pearls Medical Student Teaching Award, University of Pennsylvania
 
2006 Louis Duhring Outstanding Clinical Specialist
Award University of Pennsylvania Health System 
 
2006 100 Top Golfer Doctors in the United States, Golf Digest
 
2006 Top Doctor, General Surgery, Philadelphia Magazine
 
2006 Top Doctor, Surgical Oncology, Philadelphia Magazine 
 
2005 Top Doctor, Surgical Oncology, Philadelphia Magazine
 
2004 - 2005 Resident Faculty Teaching Award, University of Pennsylvania
 
2003 Faculty selection to the Alpha Omega Alpha
Medical Honor Society (selected by University of Pennsylvania medical students)   
 
2002 Castle Connolly’s American Top Doctors
 
2001 - 2002 Penn Pearls Medical Student Teaching Award, University of Pennsylvania
 
2001 - 2002 Resident Faculty Teaching Award, University of Pennsylvania
 
1999 Honoree, Crusader Ball, American Cancer Society
 
1999 Top Doctor, Surgical Oncology, Philadelphia  Magazine
 
1997 - 1998 Resident Faculty Teaching Award, University of Pennsylvania
 
1997 - 1998 Penn Pearls Medical Student Teaching Award, University of Pennsylvania
 
1997 - 1998 Resident Faculty Teaching Award, University of Pennsylvania
 
1996 Top Doctor, Surgical Oncology, Philadelphia Magazine
 
1991 Nusz Achievement Award for outstanding chief resident
 
1983 Henry Asbury Christian Award for excellence in academics and research
 
1980 - 1981 Dean's Office Research Award, Harvard Medical School
 
1979 The Dean's Scholar
 
1977 - 1979 Knapp Research Scholarship, University of Wisconsin
 
1978 Phi Beta Kappa
 
1976 Vilas Chancellor's Scholar

Dr. Douglas Fraker

 
footer Terms of Use Legal Disclaimer Site Map Contact Us Financial Assistance About Penn Medicine Privacy Statement
penn medicine